STOCK TITAN

[Form 4] Medifast, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Medifast director Elizabeth A. Geary received 11,168 restricted stock units (RSUs) on June 25, 2025 as part of the company's Director's Deferred Compensation Plan. The RSUs were granted at $0 cost and will fully vest on June 25, 2026.

Key details:

  • Each RSU represents the right to receive one share of Medifast common stock
  • The grant was made under the Amended and Restated 2012 Share Incentive Plan
  • Following the transaction, Geary directly owns 19,545 shares
  • The RSUs were granted in connection with annual director compensation

This Form 4 filing indicates standard director equity compensation practices at Medifast, with a one-year vesting period for director RSU grants.

La direttrice di Medifast, Elizabeth A. Geary, ha ricevuto 11.168 unità di azioni vincolate (RSU) il 25 giugno 2025 nell'ambito del Piano di Compensazione Differita per i Direttori della società. Le RSU sono state assegnate a costo zero e matureranno completamente il 25 giugno 2026.

Dettagli principali:

  • Ogni RSU rappresenta il diritto a ricevere una azione ordinaria di Medifast
  • L'assegnazione è stata effettuata ai sensi del Piano Incentivi Azionari 2012 modificato e aggiornato
  • Dopo questa operazione, Geary possiede direttamente 19.545 azioni
  • Le RSU sono state concesse come parte della compensazione annuale per i direttori

Questo deposito del Modulo 4 riflette le consuete pratiche di compensazione azionaria per i direttori di Medifast, con un periodo di maturazione di un anno per le RSU concesse ai direttori.

La directora de Medifast, Elizabeth A. Geary, recibió 11,168 unidades de acciones restringidas (RSU) el 25 de junio de 2025 como parte del Plan de Compensación Diferida para Directores de la empresa. Las RSU se otorgaron a costo cero y se consolidarán completamente el 25 de junio de 2026.

Detalles clave:

  • Cada RSU representa el derecho a recibir una acción común de Medifast
  • La concesión se realizó bajo el Plan de Incentivos de Acciones Enmendado y Restablecido de 2012
  • Tras la transacción, Geary posee directamente 19,545 acciones
  • Las RSU se otorgaron en relación con la compensación anual para directores

Esta presentación del Formulario 4 indica las prácticas estándar de compensación de acciones para directores en Medifast, con un período de consolidación de un año para las concesiones de RSU a directores.

메디패스트 이사 엘리자베스 A. 기어리2025년 6월 25일 회사의 이사회 이연 보상 계획의 일환으로 11,168 제한 주식 단위(RSU)를 받았습니다. 이 RSU는 무상으로 부여되었으며 2026년 6월 25일에 완전히 취득됩니다.

주요 내용:

  • 각 RSU는 메디패스트 보통주 1주를 받을 권리를 나타냅니다
  • 부여는 2012년 개정 및 재확인된 주식 인센티브 계획에 따라 이루어졌습니다
  • 거래 후 기어리는 직접 19,545주를 보유하게 됩니다
  • RSU는 연간 이사 보상과 관련하여 부여되었습니다

이 Form 4 제출은 메디패스트의 표준 이사 주식 보상 관행을 보여주며, 이사 RSU 부여에 대해 1년의 취득 기간이 적용됩니다.

La directrice de Medifast, Elizabeth A. Geary, a reçu 11 168 unités d'actions restreintes (RSU) le 25 juin 2025 dans le cadre du Plan de Rémunération Différée des Administrateurs de la société. Les RSU ont été attribuées à coût nul et seront entièrement acquises le 25 juin 2026.

Détails clés :

  • Chaque RSU donne droit à une action ordinaire de Medifast
  • L'attribution a été réalisée sous le Plan d'Incitation aux Actions modifié et restitué de 2012
  • Après la transaction, Geary détient directement 19 545 actions
  • Les RSU ont été attribuées dans le cadre de la rémunération annuelle des administrateurs

Ce dépôt du formulaire 4 reflète les pratiques standard de rémunération en actions des administrateurs chez Medifast, avec une période d'acquisition d'un an pour les attributions de RSU aux administrateurs.

Medifast-Direktorin Elizabeth A. Geary erhielt am 25. Juni 2025 im Rahmen des Director's Deferred Compensation Plan des Unternehmens 11.168 Restricted Stock Units (RSUs). Die RSUs wurden zu Nullkosten gewährt und werden am 25. Juni 2026 vollständig unverfallbar.

Wichtige Details:

  • Jede RSU berechtigt zum Erhalt einer Stammaktie von Medifast
  • Die Zuteilung erfolgte gemäß dem geänderten und neu gefassten Aktienanreizplan von 2012
  • Nach der Transaktion besitzt Geary direkt 19.545 Aktien
  • Die RSUs wurden im Zusammenhang mit der jährlichen Vergütung der Direktoren gewährt

Diese Form 4-Meldung zeigt die üblichen Aktienvergütungspraktiken für Direktoren bei Medifast mit einer einjährigen Vesting-Periode für RSU-Zuteilungen an Direktoren.

Positive
  • None.
Negative
  • None.

La direttrice di Medifast, Elizabeth A. Geary, ha ricevuto 11.168 unità di azioni vincolate (RSU) il 25 giugno 2025 nell'ambito del Piano di Compensazione Differita per i Direttori della società. Le RSU sono state assegnate a costo zero e matureranno completamente il 25 giugno 2026.

Dettagli principali:

  • Ogni RSU rappresenta il diritto a ricevere una azione ordinaria di Medifast
  • L'assegnazione è stata effettuata ai sensi del Piano Incentivi Azionari 2012 modificato e aggiornato
  • Dopo questa operazione, Geary possiede direttamente 19.545 azioni
  • Le RSU sono state concesse come parte della compensazione annuale per i direttori

Questo deposito del Modulo 4 riflette le consuete pratiche di compensazione azionaria per i direttori di Medifast, con un periodo di maturazione di un anno per le RSU concesse ai direttori.

La directora de Medifast, Elizabeth A. Geary, recibió 11,168 unidades de acciones restringidas (RSU) el 25 de junio de 2025 como parte del Plan de Compensación Diferida para Directores de la empresa. Las RSU se otorgaron a costo cero y se consolidarán completamente el 25 de junio de 2026.

Detalles clave:

  • Cada RSU representa el derecho a recibir una acción común de Medifast
  • La concesión se realizó bajo el Plan de Incentivos de Acciones Enmendado y Restablecido de 2012
  • Tras la transacción, Geary posee directamente 19,545 acciones
  • Las RSU se otorgaron en relación con la compensación anual para directores

Esta presentación del Formulario 4 indica las prácticas estándar de compensación de acciones para directores en Medifast, con un período de consolidación de un año para las concesiones de RSU a directores.

메디패스트 이사 엘리자베스 A. 기어리2025년 6월 25일 회사의 이사회 이연 보상 계획의 일환으로 11,168 제한 주식 단위(RSU)를 받았습니다. 이 RSU는 무상으로 부여되었으며 2026년 6월 25일에 완전히 취득됩니다.

주요 내용:

  • 각 RSU는 메디패스트 보통주 1주를 받을 권리를 나타냅니다
  • 부여는 2012년 개정 및 재확인된 주식 인센티브 계획에 따라 이루어졌습니다
  • 거래 후 기어리는 직접 19,545주를 보유하게 됩니다
  • RSU는 연간 이사 보상과 관련하여 부여되었습니다

이 Form 4 제출은 메디패스트의 표준 이사 주식 보상 관행을 보여주며, 이사 RSU 부여에 대해 1년의 취득 기간이 적용됩니다.

La directrice de Medifast, Elizabeth A. Geary, a reçu 11 168 unités d'actions restreintes (RSU) le 25 juin 2025 dans le cadre du Plan de Rémunération Différée des Administrateurs de la société. Les RSU ont été attribuées à coût nul et seront entièrement acquises le 25 juin 2026.

Détails clés :

  • Chaque RSU donne droit à une action ordinaire de Medifast
  • L'attribution a été réalisée sous le Plan d'Incitation aux Actions modifié et restitué de 2012
  • Après la transaction, Geary détient directement 19 545 actions
  • Les RSU ont été attribuées dans le cadre de la rémunération annuelle des administrateurs

Ce dépôt du formulaire 4 reflète les pratiques standard de rémunération en actions des administrateurs chez Medifast, avec une période d'acquisition d'un an pour les attributions de RSU aux administrateurs.

Medifast-Direktorin Elizabeth A. Geary erhielt am 25. Juni 2025 im Rahmen des Director's Deferred Compensation Plan des Unternehmens 11.168 Restricted Stock Units (RSUs). Die RSUs wurden zu Nullkosten gewährt und werden am 25. Juni 2026 vollständig unverfallbar.

Wichtige Details:

  • Jede RSU berechtigt zum Erhalt einer Stammaktie von Medifast
  • Die Zuteilung erfolgte gemäß dem geänderten und neu gefassten Aktienanreizplan von 2012
  • Nach der Transaktion besitzt Geary direkt 19.545 Aktien
  • Die RSUs wurden im Zusammenhang mit der jährlichen Vergütung der Direktoren gewährt

Diese Form 4-Meldung zeigt die üblichen Aktienvergütungspraktiken für Direktoren bei Medifast mit einer einjährigen Vesting-Periode für RSU-Zuteilungen an Direktoren.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Geary Elizabeth A.

(Last) (First) (Middle)
C/O MEDIFAST, INC.
100 INTERNATIONAL DRIVE

(Street)
BALTIMORE MD 21202

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MEDIFAST INC [ MED ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/25/2025 A 11,168(1) A $0 19,545 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These restricted stock units were granted under the Medifast, Inc. Director's Deferred Compensation Plan, as Amended and Restated (the "Plan"), in connection with the payment of the reporting person's annual director fees. Each unit represents the right to receive one share of the Issuer's common stock. These shares are granted from the Issuer's Amended and Restated 2012 Share Incentive Plan and will vest in full on June 25, 2026.
Remarks:
/s/ Jason L. Groves, attorney-in-fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Medifast (MED) restricted stock units did Elizabeth Geary receive on June 25, 2025?

Elizabeth Geary received 11,168 restricted stock units of Medifast (MED) on June 25, 2025, as part of her director compensation under the Director's Deferred Compensation Plan.

When will Elizabeth Geary's MED restricted stock units vest?

The restricted stock units granted to Elizabeth Geary will vest in full on June 25, 2026, exactly one year after the grant date.

How many shares of MED stock does Elizabeth Geary own after this transaction?

Following the reported transaction, Elizabeth Geary directly owns 19,545 shares of Medifast (MED) common stock.

What was the purchase price of MED restricted stock units granted to Elizabeth Geary?

The restricted stock units were granted at $0 cost to Elizabeth Geary as part of her compensation as a director of Medifast (MED).

What is Elizabeth Geary's role at Medifast (MED)?

Elizabeth Geary serves as a Director on Medifast's (MED) Board of Directors, as indicated by the 'X' marked in the Director box on the Form 4 filing.
Medifast

NYSE:MED

MED Rankings

MED Latest News

MED Latest SEC Filings

MED Stock Data

146.29M
10.69M
2.55%
83.35%
12.75%
Personal Services
Miscellaneous Food Preparations & Kindred Products
Link
United States
OWINGS MILLS